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Interferon is used to treat hepatitis C virus infection and its cutaneous side eﬀects are well known. Recently, interferon-induced
sarcoidosis has been reported. We report a new case of sarcoidosis during pegylated interferon alfa and ribavirin treatment with
an unusual presentation in a woman with previous episodes of erythema nodusum and nodular vasculitis related to HCV.
1.Introduction
Sarcoidosis is a systemic granulomatous disorder charac-
terized by the presence of noncaseating granulomas. Its
precise pathogenesis remains unclear but several cytokines,
like interferon, may play a key role in the formation of
granulomas.
Interferon is used to treat hepatitis C virus (HCV) infec-
tion due to its antiviral and immunomodulating properties
and its cutaneous side eﬀects are well known (Table 1)
[1], being localized inﬂammatory skin reactions the most
common.
Recent reports have noticed the development of sar-
coidosis in patients receiving the combination of pegylated
interferon alfa and ribavirin for the treatment of hepatitis C.
Insomecasestherewereonlyskinlesionsbutextracutaneous
involvement was detected in other patients. We report a case
of subcutaneous sarcoidosis developed during interferon alfa
and ribavirin combined therapy for HCV infection.
2.CaseReport
A 60-year-old woman was infected by HCV (genotype 1,
stageII/IV)afterabloodtransfusionin1979.Treatmentwith
subcutaneous pegylated interferon alfa (180mcg weekly)
and oral ribavirin (800mg daily) was started in April 2007.
Tolerance was poor by fatigue, weight loss (7kg), and
depressive syndrome. After six months of treatment she
suﬀered a cutaneous eruption of painful, mobile, small,
and subcutaneous nodules on her arms and legs (Figure 1).
She had history of several episodes of subcutaneous lesions
biopsied as erythema nodosum and recurrent nodular
vasculitis.
A skin biopsy revealed multiple noncaseating granulo-
mas in the septal and lobulillar adipose tissue consistent
with sarcoidosis. Special stains for bacterial, fungal, and
mycobacterial organisms were negative. Laboratory studies
demonstrated a moderate lymphopenia (2,57 × 109/L),
anemia (hemoglobine 10.2g/dL), and elevated angiotensin-
converting enzyme (62UI/L). The remaining studies (chest
X-ray, thoracic and abdominal computed tomographic,
pulmonar function testing, calcium serum levels, as well
as tumoral and inﬂammatory markers) showed no data of
systemic sarcoidosis.
Treatment was discontinued and the skin lesions cleared
after 2 months. Hepatitis remained stable with undetectable
viral load and normal liver enzymes.
3. Comment
Chronic hepatitis C aﬀects at least 170 million people
worldwide [2] and the cutaneous lesions related to HCV are2 Dermatology Research and Practice
Table 1: Cutaneous side eﬀects of interferon.
Most common Pruritus, xerosis, eczema, and localized inﬂammation at injection site
Relatively common Psoriasis, lichen planus, and vitiligo
Isolated
Eosinophilic pustular folliculitis, erythematosus lupus, Meyerson’s naevi, facial erythema, hypopigmented
atrophic plaques, hyperpigmentation, alopecia, Sweet’s syndrome, calciﬁed nodules, sclerodermatous graft
versus host disease, cutaneous necrosis, ﬁxed drug eruption, rheumatoid artritis, panniculitis, pemphigus
foliaceus, Raynaud’s phenomenon, vasculitis, and urticaria
Figure 1: Subcutaneous nodule on the hand.
very diverse. Several types of panniculitis, such as nodular
vasculitis and erythema nodosum, have been reported [3].
Treatment regimens used for chronic hepatitis include
interferon alfa (IFN-α) monotherapy, INF-α plus ribavirin,
and most recently peginterferon alfa, which has replaced
classic IFN-α as the ﬁrst-line drug in combination with
ribavirin, specially in more resistant viral genotypes 1, 4, 5,
and 6 [4, 5]. Pegylated interferon alfa, synthesized by adding
a polyethylene glycol molecule to the standard interferon
structure, has antiviral, antiproliferative, and immunomod-
ulating properties [3, 5].
The use of IFN-α is associated with several side eﬀects
(fatigue, fever, myalgia,...) that occur in 40%–55% of
patients, and cutaneous events (pruritus, rash,...)r e p o r t e d
in up to 20% of patients [3]. It may induce in addition some
autoimmune diseases (tiroiditis, lupus erythematosus,...)
[4, 6–8]. Sarcoidosis is another recognized adverse eﬀect of
IFN-alfa.
Sarcoidosis is a systemic disease characterized by the
presence of noncaseating granulomas. Although its exact
etiology remains unclear, it is thought to represent an exag-
gerated immune response to antigenic stimuli (infections,
malignancies, environmental factors,...)[ 4, 6, 9, 10]. Cell
immunity is involved and cytokines like interferons lead a
clonal proliferation of T lymphocytes and diﬀerentiation of
macrophage cells into epithelioid cells; both mechanisms
play an important role in the genesis of granuloma [4, 6].
In sarcoidosis there appears to be a predominance of a
helper T cells Type 1 (Th1) immune response and Th2 lym-
phocytes are relatively inactivated in the granulomas. IFN-α
stimulates the diﬀerentiation of Th1-type lymphocytes and
reduction of the activation of Th2 lymphocytes, favoring the
formation of granulomas in susceptible patients [4, 6, 7].
Pegylated interferon alfa was found to be superior to classic
IFN-α for enhancement of Th1-immune response and it
increases the risk of developing sarcoidosis when compared
with standard IFN-α [11].
Ribavirin is a nucleoside analog of guanosine that
enhances the Th1 response and inhibits Th2 production
[3, 5, 6]. It explains that combination therapy with IFN-α
and ribavirin is more eﬀective in treating hepatitis C virus
and it also may further predispose patients to sarcoidosis.
We think that upregulation of the Th1 immune response
by pegylated interferon alfa and ribavirin in the presence of
an antigenic trigger may play a key role for the induction
of sarcoidosis in susceptible individuals. HCV may act as an
antigenic trigger. Since 1987 when the ﬁrst case of pulmonar
sarcoidosis following interferon therapy was published,
there have been published more than 20 observations of
sarcoidosis related to interferon, in most of them combined
with ribavirin.
The time to the onset of interferon-induced sarcoidosis
ranges from 15 days to 30 months after the starting of
treatment. Men and women are equally aﬀected [4, 6].
Skin manifestations appear in more than 50% of cases,
and patches are the most common form of presentation,
but other dermatological signs (subcutaneous nodules,
scar inﬁltration,...) have been reported. Nondermatological
symptoms were also observed, being pulmonar involvement
the most frequent [4–8]. However, these symptoms are
nonspeciﬁc and can resemble the usual side eﬀects of IFN-
α; then it is possible that interferon-induced sarcoidosis is
underestimated. This underlines the importance of derma-
tological examination that can provide helpful diagnosis.
Usually interferon-induced sarcoidosis follows a benign
course. In some cases cutaneous lesions were resolved
without treatment in a few months and it was possible to
continuehepatitistreatmentwithcarefulfollow-upandclose
monitoring of systemic problems. However, there are cases
where discontinuation of interferon therapy is necessary and
even treatment with systemic steroids [4, 10].
In summary, it is known that HCV infection may be
associated with many dermatologic diseases. Our patient
had recurrent episodes of erythema nodosum and nodular
vasculitis associated with HCV. Development of sarcoidosis
may be related to an antigenic trigger such as HCV in a
susceptible patient with an enhanced Th1 response from
pegylated interferon and ribavirin.
We report a case of interferon-induced sarcoidosis with
an unusual presentation as subcutaneous nodules, without
extracutaneous involvement, and it resolved completely after
interferon was withdrawn.Dermatology Research and Practice 3
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